Aura Biosciences (NASDAQ:AURA) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Aura Biosciences (NASDAQ:AURA) issued its earnings results on Tuesday. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02, Zacks reports.

Aura Biosciences Stock Down 1.1 %

Shares of NASDAQ:AURA traded down $0.12 during midday trading on Wednesday, reaching $10.53. The company’s stock had a trading volume of 36,363 shares, compared to its average volume of 175,139. The stock has a fifty day moving average of $9.69 and a 200 day moving average of $8.49. Aura Biosciences has a twelve month low of $6.63 and a twelve month high of $12.38.

Analyst Ratings Changes

AURA has been the subject of a number of recent research reports. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. HC Wainwright raised their price objective on Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Scotiabank raised their price target on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Friday, October 18th. Cowen reissued a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Finally, BTIG Research raised their price target on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $23.00.

Insider Buying and Selling at Aura Biosciences

In other news, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the sale, the chief technology officer now owns 121,132 shares of the company’s stock, valued at $1,193,150.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Aura Biosciences news, insider Los Pinos Elisabet De sold 9,200 shares of the stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $10.74, for a total transaction of $98,808.00. Following the transaction, the insider now owns 320,647 shares in the company, valued at approximately $3,443,748.78. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the sale, the chief technology officer now directly owns 121,132 shares in the company, valued at approximately $1,193,150.20. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 67,259 shares of company stock valued at $780,699. 5.40% of the stock is owned by insiders.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.